Systematic Review and Network Meta‐Analysis on the Efficacy of Evolocumab and Other Therapies for the Management of Lipid Levels in Hyperlipidemia

Systematic Review and Network Meta‐Analysis on the Efficacy of Evolocumab and Other Therapies for the Management of Lipid Levels in Hyperlipidemia

BackgroundThe proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors evolocumab and alirocumab substantially reduce low‐density lipoprotein cholesterol (LDL‐C) when added to statin therapy in patients who need additional LDL‐C reduction. Methods and ResultsWe conducted a systematic review...

Full description

Bibliographic Details
Main Authors: Peter P. Toth, Gillian Worthy, Shravanthi R. Gandra, Naveed Sattar, Sarah Bray, Lung‐I. Cheng, Ian Bridges, Gavin M. Worth, Ricardo Dent, Carol A. Forbes, Sohan Deshpande, Janine Ross, Jos Kleijnen, Erik S. G. Stroes
Format: Article
Language:English
Published: Wiley 2017-10-01
Series:Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Subjects:
alirocumab
evidence‐based medicine
evolocumab
ezetimibe
lipids
low‐density lipoprotein cholesterol
Online Access:https://www.ahajournals.org/doi/10.1161/JAHA.116.005367

Internet

https://www.ahajournals.org/doi/10.1161/JAHA.116.005367

Similar Items